Abstract
Various inflammatory biomarkers show prognostic potential for multiple sclerosis (MS)-risk after clinically isolated syndromes. However, biomarkers are often examined singly and their interrelation and precise aspects of their associated pathological processes remain unclear. Clarification of these relationships could aid the appropriate implementation of prognostic biomarkers in clinical practice.
Originalsprog | Engelsk |
---|---|
Tidsskrift | P L o S One |
Vol/bind | 8 |
Udgave nummer | 10 |
Sider (fra-til) | e77163 |
ISSN | 1932-6203 |
DOI | |
Status | Udgivet - 2013 |